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Abstract
The noninvasive assessment of anticancer treatment
efficacy is very important for the improvement of
therapeutic window. The purpose of the present study
was to evaluate the antitumoral effects of the vas-
cular targeting agent, combretastatin A-4 phosphate
(CA-4-P), at selected time points after repeated intra-
peritoneal drug administrations (25 mg/kg), using
diffusion-weighted magnetic resonance imaging (DW-
MRI). The experiments were performed during an over-
all follow-up period of 3 weeks on WAG/Rij rats with
subcutaneously growing rhabdomyosarcomas. Each
animal served as its own baseline. The DW-MRI studies
were quantified by calculating the apparent diffusion
coefficient (ADC) for different low and high b -values to
separate the effects on tumor vasculature and cellular
integrity. The changes in ADC as well as the extent
of necrosis development (proportional to the tumor
volume), measured on the MR images, were of com-
parable magnitude after each treatment. All ADC values
showed a significant decrease at 6 hours, followed by
a significant increase at 2 days for various CA-4-P ad-
ministrations. DW-MRI allowed us to monitor both re-
duction in perfusion and changes in the extent of tumor
necrosis after CA-4-P injection. Repeated CA-4-P ad-
ministration retains efficacy in rat rhabdomyosarcomas,
with similar findings after each drug administration.
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Introduction
To overcome the limits of classic tumor treatments such
as chemotherapy and radiation therapy, new approaches
must be developed. One possibility is to selectively target
vascularity to inhibit the development of new blood vessels
(antiangiogenesis), or to destroy postangiogenic vessels (vas-
cular targeting) in tumors [1,2].
One family of vascular targeting agents (VTAs) is com-
prised of low-molecular-weight compounds, which inhibit tu-
bulin polymerization with inherent microtubule destabilization,
causing acute vascular shutdown in solid tumors [3,4]. One of
the lead compounds in this family is combretastatin A-4 phos-
phate (CA-4-P). Acute events on tumor vessel structure and
function, with subsequent extensive tumor necrosis, have been
described for this compound in various rodent models and
some explanations on the temporal mechanism of action have
been discussed [5–10]. Although the antitumor effects dem-
onstrated in these preclinical studies were severe, a thin rim
of viable tumor tissue consistently remained, from which ex-
pansion rapidly occurred. These studies were based on single
treatments with doses inducing little or no systemic toxicity.
In experimental settings using CA-4-P, the response evalu-
ation has been performed with various noninvasive methods
such as 31P magnetic resonance spectroscopy and dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI).
This follow-up was studied up to, at most, 24 hours after admi-
nistration [11,12]. The dynamic imaging results were consistent
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with vascular volume and perfusion changes. With the ex-
ception of growth delay evaluation [7,13,14], no information
is available on the efficacy of repeated drug administration
in preclinical studies.
In phase I clinical trials, escalating doses of CA-4-P were
applied at regular intervals, and the effects were evaluated
with DCE-MRI and positron emission tomography (PET), in
addition to clinical and pharmacokinetic parameters [15–18].
Yet, the effects on the tumors were not studied specifically
after each drug administration.
We have shown earlier, using the rat rhabdomyosarcoma
tumor model, that the antitumor effect of a single treatment
with CA-4-P can be monitored noninvasively using diffusion-
weighted magnetic resonance imaging (DW-MRI) [19].
The aim of the present study was to noninvasively eval-
uate the effects of CA-4-P on rat rhabdomyosarcomas after
three equally spaced intraperitoneal injections over a period
of 3 weeks using DW-MRI, and to relate the time course of
changes in necrotic versus viable tumor tissue.
Materials and Methods
Tumor Model
The experiments were performed on 13 male adult
WAG/Rij rats, weighing 280 to 300 g. The animals were
wrapped in a warm towel to keep the body temperature
constant during the average imaging period of 10 minutes.
Rhabdomyosarcoma tumors (1-mm3 pieces) were implanted
subcutaneously in the flank region at the level of the kidneys
on opposite sides. The baseline tumor volume before treat-
ment was 3.6 ± 1.3 cm3, reached at 2 weeks postimplantation.
The study protocol was approved by the local ethical
committee for animal care and use. Rats were kept in a
conventional housing facility and given access to food and
water ad libitum.
MRI
The rats were examined in a 1.5-T whole-body MR
system (SonataVision; Siemens, Erlangen, Germany) with
a 40-mT/m maximum gradient capability. A four-channel
phased-array wrist coil was used to obtain all MR images,
allowing parallel imaging (parallel imaging reduction factor
[generalized autocalibrating partially parallel acquisition,
or GRAPPA] of two in all series). To avoid movement, rats
were placed supine into a plastic holder with tube connec-
tion to a gas anesthesia system (2% isoflurane in a 20%
oxygen and 80% room air mixture). For intravenous access,
the penile vein was cannulated.
A coronal T1-weighted spin-echo sequence was used as
localizer. A transverse T1-weighted spin-echo (553 msec/
15msec [repetition time/echo time], matrix size of 120 256)
and a T2-weighted turbo spin-echo sequence (5860 msec/99
msec, matrix size of 160  256, turbo factor 19) were per-
formed with a section thickness of 2 mm and an intersec-
tion gap of 0.2 mm. The field of view was 81.3  130 mm2,
covering both tumors entirely (20 slices). The time of acqui-
sition was 1:32 minutes for the T1-weighted sequence with
two averages and 1:34 minutes for the T2-weighted se-
quence with three averages.
A DW-MRI echo-planar sequence was performed with a
large range of b-values (b = 0, 50, 100, 150, 200, 250, 300,
500, 750, and 1000 sec/mm2). The following parameters
were used for this sequence: TR = 3300 milliseconds, TE =
124 milliseconds, matrix size of 96  192, four averages,
and a total time of acquisition of 2:35 minutes. The duration
of both diffusion-sensitizing gradient pulses was 25 milli-
seconds each, without gap between the positive and nega-
tive lobes. Gradient strength was adjusted for each b -value.
Apparent diffusion coefficient (ADC) maps were calculated
from the native diffusion images with the built-in software
tools of the MRI scanner.
All sequences were acquired with the same geometry
to maintain comparability between the different imaging
sequences.
Study Design
The abovedescribed MR protocol was performed on
13 rats with bilateral tumors (n = 26).
Six rats (12 tumors) were examined before and after
each of the three intraperitoneal CA-4-P (OXiGENE, Water-
town, MA) injections at a dose of 25 mg/kg body weight
(based on earlier experiments) [7] administered with an in-
terval period of 9 days. Treatment monitoring was performed
by applying the entire MRI protocol according to the following
schedule: 1) baseline study prior to first CA-4-P administra-
tion; 2) imaging at 6 hours, 2 days, and 9 days (baseline
for second treatment) after the first CA-4-P administration;
3) 6 hours, 2 days, and 9 days (baseline for third treatment)
after the second CA-4-P administration; and 4) 6 hours and
2 days (three of six animals) after the third drug adminis-
tration. After the third CA-4-P administration, three of these
animals were sacrificed at 6 hours (n = 6 tumors) and the
remaining three at 2 days (n = 6 tumors).
For correlation between MRI and histopathology after
a single CA-4-P administration, four rats were used: one
animal (n = 2 tumors) was sacrificed before treatment, and
one animal at 6 hours, 2 days, and 9 days, respectively.
As controls, the remaining three rats (n = 6 tumors)
underwent the same study protocol without CA-4-P treat-
ment to compare tumor growth and to assess potential in-
fluences of MR examinations on animals and tumor analysis.
Image Analysis
Image analysis was performed off-line on a LINUX work-
station using a dedicated software (BioMAP; Novartis, Basel,
Switzerland). In the transverse T1-weighted sequence, the
entire tumors were manually delineated on each slice by two
observers in consensus. For each tumor, the delineations
on all slices were merged to produce a three-dimensional
region of interest (ROI) per tumor from which the system
automatically calculated the volume.
Analysis of the DW-MRI images was performed in a first
step by copying the ROIs of the T1-weighted images onto the
ADC maps at each time point. In a second step, several cir-
cular ROIs were placed in the periphery (the outer 5 mm) as
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well as in the center (more than 10 mm from the edge) of
each tumor. The respective ROIs were merged to obtain one
center ROI and one peripheral ROI for each tumor. After-
ward, the ROIs of the ADC maps were copied to the cor-
responding original diffusion images, from which the average
intensities for each different b -value could be obtained. The
signal intensities of the ADC maps from the DW-MR images
were graded as hypointense, isointense, and hyperintense
by visual comparison.
The ADC is a quantitative parameter calculated from
the diffusion-weighted MR images. Le Bihan et al. [20] hy-
pothesized that the ADC reflects not only diffusion but also
microcirculation of blood (perfusion). Using lower b -values
in the ADC calculations shows a greater influence of per-
fusion, whereas by using only higher b -values, the true
diffusion coefficient of the tissue is approximated. The hy-
pothesis has been validated for this rat tumor model in a
previous study; a strong correlation was observed between
the perfusion influence in the DW-MR images and the per-
fusion parameters from a dynamic contrast-enhanced MR
sequence after treatment with CA-4-P [21]. In the present
study, the ADCs of the tumors were therefore calculated
separately for a range of low b -values (b = 0, 50, and
100 sec/mm2; ADClow) and high b -values (b = 500, 750,
and 1000 sec/mm2; ADChigh) to better differentiate the rela-
tive contribution of perfusion and true diffusion. The ADC
values were calculated using a least squares solution of
the following system of equations:
SðiÞ ¼ S0expðbiADCÞ
where S(i ) is the signal intensity measured on the i th
b -value image and bi is the corresponding b -value. S0 is
a variable that estimates the intrinsic signal intensity (for
b = 0 sec/mm2). To limit the influence of noise (from the sig-
nal measurements) on ADC calculations, diffusion images
with at least three different b-values were used for calcu-
lations of ADChigh and ADClow.
The amount of necrosis in the tumors was estimated on
the ADC maps (calculated from all used b-value images) by
measuring the in-plane ratio of necrotic diameter versus
total diameter of the tumor in the two perpendicular main
directions of a central tumor slice. To reduce intraobserver
variability and minimize the influence of the chosen tumor
slice, the measurement was repeated on three of the center
slices through the tumor and averaged afterward.
Histologic Analysis and Correlation with Imaging Results
Histopathologic correlation was obtained 6 hours, 2 days,
and 9 days after a single CA-4-P administration, and 6 hours
and 2 days after the third treatment. After surgical excision
of the tumors, sections were made in the transverse plane
corresponding to the MR sections. The tumors were fixed in
a 10% formaldehyde solution. Following paraffin embedding,
5-mm sections were stained with hematoxylin and eosin.
Tissue sections were assessed for cell viability (discernible
heterochromatin and euchromatin in the nucleus, occurrence
of mitoses) and vasculature (vessel constriction, dilatation,
or congestion). All sections were screened at different mag-
nifications up to 400 by an experienced histopathologist
(E.K.V.) who was blinded to all treatment and MRI-related
information. Thereafter, the histologic sections were com-
pared with the corresponding transverse ADC maps.
Statistical Analysis
Statistical analysis was carried out with the software
packages Microsoft Excel 9.0 and Analyse-It 1.68 (Analyse-
It Ltd., Leeds, England, UK). Absolute numeric data are
reported as mean ± standard deviation (SD), whereas per-
centage values are given compared to the baseline value.
For statistical analysis, comparison between the treated
rats at the subsequent time points was performed using the
paired two-tailed Student’s t test, whereas comparison of
the treated rats to the controls was performed using unpaired
two-tailed Student’s t tests. A P-value smaller than .05 was
considered significant.
Results
Tumor Volume
The tumor volume at the respective time points is given
in Figure 1 for the treated rats as well as for the control
animals. At 9 days after the first CA-4-P administration, a
significant difference was found between the tumor vol-
umes of the treated rats (n = 12 tumors) as compared to
the control rats (n = 6 tumors) (P = .007). This difference
was more significant at later time points: P = .004 after
11 days (2 days after the second CA-4-P administration),
P = .002 after 18 days, and P = .0002 after 20 days (2 days
after the third CA-4-P administration).
Before CA-4-P Administration
The rat rhabdomyosarcomas evaluated at the start of
the present study showed a variable proportion of necrosis
on DW-MRI, mostly located in the central part of the tumors.
Figure 1. Bar charts representing the tumor volume of the CA-4-P– treated
rats (n) compared to the controls (5). A significant difference in volumes (P =
.007) can already be observed between treated and untreated tumors after
9 days. The decrease in tumor volume observed between 18 and 20 days
and the related increased SD in the treated tumors are due to the randomly
selected sacrifice of three (of six) of the treated rats for histology on day 18.
Error bars, ± SD.
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The ADCaverage of the entire tumor volume before treat-
ment was 1.24 ± 0.15 ( 103 mm2/sec), whereas ADClow
was 1.62 ± 0.18 ( 103 mm2/sec) and ADChigh was 1.14 ±
0.15 ( 103 mm2/sec). When looking at the values of cen-
ter and periphery separately, higher ADC values were found
in the center of the tumor (in 103 mm2/sec, ADCaverage
of 1.69, ADClow of 1.88, and ADChigh of 1.64) and lower
values in the periphery (in 103 mm2/sec, ADCaverage of 1.11,
ADClow of 1.43, and ADChigh of 1.05).
After First CA-4-P Administration
Functional changes (n = 12 tumors)
ADC of the whole tumor volume. Six hours after the first
CA-4-P treatment (Figure 2B), no overall visual changes in
hypointense and hyperintense regions compared to the
baseline (Figure 2A) could be appreciated on the ADC
maps, but all calculated ADC values decreased significantly
(ADCaverage, P < .001; ADClow, P < .001; ADChigh, P = .002)
(Table 1). At 2 days after the first treatment, almost the
entire tumor volume was uniformly hyperintense on the
ADC maps (Figure 2C) and all calculated ADC values
were significantly increased (P < .001). At 9 days post-
injection, a broad hypointense rim was seen surrounding
a large hyperintense center (Figure 2D). At the same time,
both ADCaverage and ADChigh decreased significantly (P <
.001), whereas the ADClow showed no significant changes
compared to the previous time point (P = .08) (Figure 3).
ADC of ROIs at the center and periphery of the tumor. At
6 hours after the first CA-4-P administration, all ADC values
in the center and periphery showed a significant decrease
compared to baseline, except for the ADChigh in the periph-
eral ROIs (ADCaverage, P = .01 and P = .04; ADClow, P = .02
and P < .001; and ADChigh, P = .01 and P = .49, for the center
and periphery, respectively; Figure 4). On day 2 after treat-
ment, all ADC values increased significantly (P = .007 for
ADClow in the center of the tumor, P < .001 for all other ADC
values). At 9 days, again a significant decrease was found
in all ADC values (P < .005), except for the ADChigh in the
center (P = .24).
Correlation between histopathology and ADC maps Six
hours after drug administration, histopathology showed
some interstitial edema at the transition between the tumor
Figure 2. ADC maps of transverse DW-MRI images of a rat rhabdomyosarcoma, calculated using all b-values (ADCaverage). The images are given before (A)
and at different time points in between and after repeat CA-4-P administration: 6 hours (B), 2 days (C), 9 days (D), 9 days and 6 hours (E), 11 days (F), 18 days (G),
18 days and 6 hours (H), and 20 days (I). Doses of CA-4-P were administered every 9 days after day 0 (A), at day 9 (D), and at day 18 (G). The 9-day time points
(D and G) after each administration served as baseline for the following evaluations. Each row represents the time points before (A, D, and G), at 6 hours (B, E, and
H), and at 2 days (C, F, and I) after each CA-4-P administration. Changes on the ADC map were similar after each CA-4-P administration. Before the injection (A,
D, and G), a central hyperintensity was visible with a broad hypointense periphery, corresponding to a necrotic center surrounded by solid tumor tissue. No visible
changes were found 6 hours later (B, E, and H), indicating still viable tumor tissue in the periphery. After 2 days, the entire tumor volume became hyperintense (C,
F, and I), showing extension of the necrotic area. This was slightly less pronounced 2 days after the third CA-4-P administration in this example tumor (I).
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periphery and the necrotic center. The tumor cells in the
periphery had still a viable profile (several mitoses seen),
whereas the vessels were congested or constricted. At this
time point after CA-4-P administration, the ADCmaps clearly
showed a broad remaining hypointense rim with a hyper-
intense center (Figure 2B), similar to the pretreatment
images (Figure 2A). These findings suggested a remaining
viable tumor tissue in the periphery, which was confirmed
with histologic examination.
The histology at 2 days showed a strongly reduced size
of the periphery containing a high rate of mitoses. In parallel,
the necrotic portion of the tumor was substantially larger
with only pyknotic cells present. At this time point, the ADC
maps showed extensive hyperintensity (Figure 2C).
Seven days later, a broad rim of viable tumor cells with
a very high rate of mitoses was seen histologically. This
corresponded with the hypointense viable periphery on the
ADC maps surrounding the hyperintense necrotic center
(Figure 2D).
After the Second CA-4-P Administration
Functional changes (n = 12 tumors)
ADC of the whole tumor volume. The changes of DW-
MRI found after the second treatment were similar to the
findings after the first CA-4-P injection (Figure 3, Table 1).
Six hours after the second treatment, the ADC maps
showed no visible changes from the previous time point
(Figure 2E ), but all ADC values decreased significantly
(ADCaverage and ADClow, P < .001; and ADChigh, P = .003).
Two days later, the entire tumor was hyperintense on the
ADC maps (Figure 2F ) and a significant increase was
observed for all ADC values (P < .001). At 9 days after the
Table 1. Absolute ( 103 mm2/sec) and Relative (%) ADC Values during Repetitive CA-4-P Administration.
Time after the First CA-4-P Administration
Before 6 hours 2 days 9 days 9 days, 6 hours 11 days 18 days 18 days, 6 hours 20 days
Whole volume
ADCaverage 1.24 ± 0.15 1.08 ± 0.19 1.78 ± 0.17 1.43 ± 0.13 1.30 ± 0.14 1.70 ± 0.25 1.34 ± 0.23 1.19 ± 0.26 1.69 ± 0.19
* (%) 100 87 145 116 106 139 108 96 138
y (%) 100 91 120 93 83 120
z (%) 100 89 122
ADClow 1.62 ± 0.18 1.13 ± 0.19 1.94 ± 0.20 1.88 ± 0.20 1.56 ± 0.24 2.05 ± 0.26 1.72 ± 0.23 1.32 ± 0.30 2.00 ± 0.14
* (%) 100 70 121 117 97 127 107 82 130
y (%) 100 83 109 92 70 111
z (%) 100 76 114
ADChigh 1.14 ± 0.15 1.00 ± 0.13 1.74 ± 0.23 1.24 ± 0.15 1.14 ± 0.13 1.58 ± 0.30 1.16 ± 0.20 1.06 ± 0.26 1.55 ± 0.19
* (%) 100 89 154 109 101 138 102 93 137
y (%) 100 92 127 93 85 127
z (%) 100 90 130
Center
ADCaverage 1.69 ± 0.36 1.55 ± 0.38 1.96 ± 0.30 2.20 ± 0.28 2.15 ± 0.24 2.16 ± 0.23 2.12 ± 0.27 2.06 ± 0.27 2.06 ± 0.14
* (%) 100 91 119 135 132 133 131 126 132
y (%) 100 98 99 97 94 93
z (%) 100 97 97
ADClow 1.88 ± 0.30 1.65 ± 0.49 2.00 ± 0.21 2.41 ± 0.23 2.29 ± 0.24 2.39 ± 0.23 2.43 ± 0.19 2.25 ± 0.21 2.32 ± 0.08
* (%) 100 87 108 131 124 129 132 122 129
y (%) 100 95 99 101 94 96
z (%) 100 93 94
ADChigh 1.64 ± 0.46 1.51 ± 0.44 1.90 ± 0.36 1.99 ± 0.32 1.99 ± 0.29 1.95 ± 0.27 1.87 ± 0.32 1.93 ± 0.28 1.81 ± 0.17
* (%) 100 92 120 128 129 127 122 124 116
y (%) 100 100 99 94 97 91
z (%) 100 104 96
Periphery
ADCaverage 1.11 ± 0.14 0.97 ± 0.21 1.80 ± 0.27 1.04 ± 0.14 0.94 ± 0.13 1.59 ± 0.32 1.210.30 0.89 ± 0.11 1.66 ± 0.18
* (%) 100 88 164 94 86 144 111 81 156
y (%) 100 91 155 119 87 168
z (%) 100 77 118
ADClow 1.43 ± 0.21 1.02 ± 0.26 1.89 ± 0.27 1.46 ± 0.33 1.04 ± 0.22 1.83 ± 0.33 1.48 ± 0.35 0.93 ± 0.20 2.00 ± 0.28
* (%) 100 71 133 103 74 129 104 66 142
y (%) 100 74 131 107 66 148
z (%) 100 66 120
ADChigh 1.05 ± 0.16 0.99 ± 0.27 1.73 ± 0.28 0.98 ± 0.13 0.88 ± 0.14 1.47 ± 0.29 1.15 ± 0.26 0.88 ± 0.12 1.55 ± 0.19
* (%) 100 95 168 94 86 141 112 85 156
y (%) 100 91 151 119 90 163
z (%) 100 79 115
*Relative changes compared to the baseline before the first CA-4-P administration.
yRelative changes compared to the baseline before the second CA-4-P administration.
zRelative changes compared to the baseline before the third CA-4-P administration.
Repeated CA-4-P Injection Monitored by DW-MRI Thoeny et al. 783
Neoplasia . Vol. 7, No. 8, 2005
second CA-4-P administration, all ADC values decreased
significantly (P < .001), and a new hypointense rim could
be appreciated on the ADC maps (Figure 2G).
ADC of the ROIs at the center and periphery of the
tumor. Six hours after the second CA-4-P administration,
only the ADClow values at both the center and periphery
decreased significantly (P = .02 and P = .003, respectively)
(Figure 4). In the periphery, the ADCaverage and ADChigh
values also decreased significantly (P = .04 and P = .02),
whereas at the center, these two values remained largely
unchanged (P = .14 and P = .97). Two days later, no signifi-
cant changes were observed in all ADC values at the center
(ADCaverage, P = .61; ADClow, P = .14; ADChigh, P = .22),
whereas all ADC values in the periphery increased signifi-
cantly (P < .001). At the 9-day time point, no significant
changes were found in the center for ADCaverage (P = .12)
and ADClow (P = .35) and a slightly significant change
for ADChigh (P = .04), whereas all ADC values in the
periphery decreased significantly (ADCaverage, P < .001;
ADClow, P = .006; and ADChigh, P = .001).
After the Third CA-4-P Administration
Functional changes
ADC of the whole tumor volume. The changes of DW-
MRI found after the third treatment were similar to the
findings following the first and second CA-4-P injections
(Figure 3, Table 1).
Six hours after the third CA-4-P administration (n = 12
tumors), no visible changes were found on the ADC maps
compared to the previous time point (Figure 2H), but again
a significant decrease was observed for all calculated ADC
values (ADCaverage and ADClow, P < .001; and ADChigh,
P = .006). At this time point, three rats were sacrificed for
histopathologic analysis of the tumors (n = 6).
At 2 days after the third injection (n = 6 tumors), the
hyperintense area of the tumors strongly increased on the
ADC maps (Figure 2I ) and the corresponding calculated
ADC values increased significantly (ADCaverage, P = .002;
ADClow, P < .001; and ADChigh, P = .004).
ADC of the ROIs at the center and periphery of the
tumor. In the tumor center, 6 hours after the third CA-4-P
administration, only the ADClow decreased significantly
(P < .001), whereas the ADCaverage and ADChigh remained
mainly unchanged (P = .19 and .22, respectively) (Figure 4).
The periphery showed a significant decrease in all ADC
values at this time point (ADCaverage, P = .002; ADClow,
P < .001; and ADChigh, P = .002). At 2 days after the
third treatment, all ADC values in the periphery were sig-
nificantly increased (ADCaverage, P < .001; ADClow, P = .001;
and ADChigh, P = .001). At the center, all ADC values re-
mained unchanged (ADCaverage,P = .86; ADClow,P = .44; and
ADChigh, P = .26).
Correlation between histopathology and ADC maps At
6 hours after the third CA-4-P administration, four of the six
excised tumors showed complete necrosis of the center
(Figure 5, A3), whereas the other two revealed some clus-
ters of remaining viable-looking tumor cells with some mito-
ses seen in the center (Figure 5, B3). In comparison to
the findings after the first treatment, the demarcation be-
tween the central necrosis and the actively proliferating
Figure 3. Bar charts showing the changes in ADC values (calculated from
the transverse DW-MRI images) over the entire tumor volume at the different
time points before and after CA-4-P administrations as indicated on the graph
(arrows). The ADCaverage values are calculated from the DW-MRI images with
all employed b-values (ADClow values from b-values: 0, 50, and 100 sec/mm
2;
ADChigh values from b-values: 500, 750, and 1000 sec/mm
2). All values are
given in percentages compared to baseline. A significant decrease was found
6 hours after each CA-4-P administration, indicating the vascular shutdown
as confirmed by histology. Thereafter, a significant increase occurred after
2 days (days 2, 11, and 20), corresponding to expansion of necrosis.
Figure 4. Bar charts showing the changes in ADC values (calculated from the
transverse DW-MRI images) of ROIs placed at the periphery of the tumors at
different time points before and after CA-4-P administrations. The time points
for injections are indicated by arrows on the graph. The ADCaverage values are
calculated from the DW-MRI images with all employed b-values (ADClow
values from b-values: 0, 50, and 100 sec/mm2; ADChigh values from b-values:
500, 750, and 1000 sec/mm2). All values are given in percentages compared
to baseline. During the first 6 hours after each CA-4-P administration, the
ADClow decreased significantly due to vascular shutdown. Two days after
each treatment, a significant increase was found for all ADC values, cor-
responding to an increase of the necrotic fraction.
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tumor in the periphery was more pronounced. The ADC
maps (Figure 2H ) showed still viable tumor tissue in the
periphery, confirmed by histologic findings. The ADCmaps of
the tumors with complete central necrosis on histology had a
higher ADC value compared to both tumors with clusters of
viable cells in the center.
At 2 days (n = 6 tumors), only a small rim of viable tumor
cells was visible on histology accompanied by extension of
the necrotic fraction. Five of the six tumors showed com-
plete necrosis of the center, corresponding to the homo-
geneous bright center in the ADC maps (Figure 2I ). In the
remaining tumor, some clusters of viable cells were visible
on histologic examination, which appeared heterogeneous
and hypointense in the center of the respective ADC map.
Necrotic Tumor Area
The necrotic tumor area at the respective time points
is given in Figure 6 for the treated rats as well as for the
control animals. In the untreated rats, a variable but per-
sistent increase in necrotic tumor area occurs. This is not
the case in the treated animals, as the tumors experience
massive necrosis induction after each CA-4-P administra-
tion. There are no significant differences between the sub-
sequent time points of maximal necrosis proportionate to
the respective tumor volumes (2-day time point after each
CA-4-P administration) (between 2 and 9 days, P = .08; be-
tween 9 and 18 days, P = .92).
Retrospective ADC Assessment
During histopathologic examinations of the repeatedly
treated tumors, three tumors (of 12) showed some remain-
ing viable-looking cells in the necrotic center. These tumors
had also the lowest ADC values in the central necrosis just
before excision. Retrospectively, these same three tumors
showed the lowest ADC values during the entire examina-
tion sequence. Even before the first treatment, these three
tumors had outlying lower values compared to the nine other
tumors in both ADCaverage and ADChigh (in 10
3 mm2/sec):
ADCaverage values were 1.15, 0.91, and 1.05 (compared to
the average of 1.24) and ADChigh values were 1.00, 0.83,
and 0.95 (compared to the average of 1.14).
Figure 5. Transverse ADC maps before the first (A1 and B1) and 6 hours after the third CA-4-P administration (A2 and B2) of two different rat rhabdomyosarcomas
(A and B). Rectangles in the ADC maps (A2 and B2) approximate the location of the shown histologic (400) panels (A3 and B3). On the ADC maps after the third
treatment (A2 and B2), three regions can be depicted in each tumor: rim (arrows), viable tissue (#), and necrosis (*). Tumors (A) and (B) have different intensities in
the necrotic center of the ADC maps (A2 and B2) (*). The higher intensity in tumor (A) corresponded histologically to complete necrosis (A3). The lower intensity in
tumor (B) corresponded to the presence of still viable cells in tumor (B) (B3). Note the well recognizable euchromatin and heterochromatin in most nuclei and some
mitotic figures (B3, arrowheads). Retrospectively, a difference between these two tumors could already be appreciated visually before the first treatment (A1 and B1).
Figure 6. Bar charts representing the percentage of necrotic tumor area of
the treated rats ( ) and the controls (5) during the follow-up sequence. In
the untreated rats, a variable but persistent increase in necrotic tumor area
occurs. This is not the case in the treated animals, as the tumors experience
massive necrosis induction 2 days after each CA-4-P administration. Error
bars, ± SD.
Repeated CA-4-P Injection Monitored by DW-MRI Thoeny et al. 785
Neoplasia . Vol. 7, No. 8, 2005
Discussion
From a clinical point of view, the evaluation of effects
developing within hours to a few days in the tumor micro-
environment after the use of anticancer agents is very
important. This information can be used to predict the
response in tumors, and allows themodulation of the ongoing
treatment. The potential of using individual tumor-adapted
treatments and the introduction of novel anticancer ther-
apies further support the need for noninvasive imaging ap-
proaches. One such novel treatment strategy, vascular
targeting using small molecules such as CA-4-P, has been
shown to induce severe intratumoral damage at doses
below the maximum tolerated dose (Refs. [3,22] and refer-
ences therein). Based on the broad information on drug
activity obtained with preclinical rodent tumors, clinical
phase I trials have been performed using escalating doses
of CA-4-P administered at regular time intervals [17,23].
The use of gadolinium-based DCE-MRI already pro-
vided useful information on the rapidly induced and severe
changes in tumor blood flow and vessel permeability after
treatment with VTAs [16,23–25]. DW-MRI has been initi-
ated recently as a potential noninvasive technique to monitor
the antitumoral effects of radiotherapy and chemotherapy
with the aim to predict therapy outcome [26–36]. In contrast
to conventional MRI, viable tumor can be differentiated from
tumor necrosis with DW-MRI [34,35]. High cellular density
is related to a low ADC value, reflecting the lack of mobility
of water protons, whereas high ADC values relate to necrotic
tissue with inherent diffusion of water protons due to loss of
cell membrane integrity [34,36]. We have already shown
earlier, using a rat rhabdomyosarcoma R1 tumor model, that
DW-MRI allows assessment of intratumoral cell integrity
changes after a single CA-4-P administration [19,21].
The present study involves the same rat tumor model,
but the set-up of the study was extended toward repeated
injections of CA-4-P and the potential of DW-MRI to eval-
uate the reproducibility of the induced intratumoral damage
after each administration. The results illustrate that CA-4-P
retained a similar efficacy after the treatment with a second
and a third equal-sized dosage. The changes in ADC values
after each treatment were of the same order of magnitude,
with an initial decrease 6 hours after treatment followed by a
strong increase at 2 days posttreatment. In a previous study
using the same tumor model, the initial ADC decrease was
found to be a result of both diffusion restriction due to
ischemia (reflected in a decrease in ADChigh) and a decrease
in perfusion (reflected by a stronger decrease in ADClow)
[21]. The subsequent increase in all ADC values coincided
with necrosis formation.
With the exception of the ADClow calculated at 6 hours
after the second and third injections, no significant change in
values was observed in the center of the tumor. The center
was identified on histology as being necrotic, both after the
third CA-4-P administration as well as in a separate series
of tumors after a single CA-4-P administration. Hence, the
ADC changes calculated in the periphery of the tumors
should determine the ADC changes of the whole tumor. The
translation was indeed proven by the measurements in the
periphery of the tumors, which showed similar significant
changes in ADCaverage, as well as in ADClow and ADChigh.
Importantly, the extent of necrosis development in relation
to the evolution in size of the tumors, as measured on the
MR images, was very similar after each drug treatment.
The parallel increase in ADC measured at 2 days after each
CA-4-P administration represents this positive response to
treatment noninvasively. The hypointense rim appreciated on
the ADC maps at 9 days after each treatment represents
viable cell-rich tissue from which tumor growth has occurred
prior to the next CA-4-P treatment. It is in this peripheral area
that the accelerated development of new pathologic vessels
takes place and provides nutrients for tumor expansion as
seen after each treatment. These newly formedmicrovessels
may provide an improved tumor perfusion, which, together
with the major influence of necrosis formation (reflected in
ADChigh), is translated in an increase in ADClow 2 days after
each CA-4-P administration. Changes in ADClow are, as
indicated by us and others, related to a change in perfusion
as well as true diffusion [19,20]. Very recently, preclinical
in vivo data have been published on the impact of cell den-
sity on the potential of microvessels to provide adequate
intratumoral perfusion [37]. In that study, the reduction of cell
density on treatment paralleled an increase in the fraction of
tumor vessels with open lumen. Such a mechanismmay play
a role in the increased ADClow at 2 days after CA-4-P
treatment when extensive necrosis is prominently present,
as measured in our study. Finally, lower values of ADC
are related to high cellular density in the tumors. A study by
Taouli et al. [38] analyzing focal liver lesions by DW-MRI
showed that metastatic lesions and hepatocellular carci-
nomas had the lowest ADC. These authors attributed this
finding to the higher tumoral content of these lesions, which
restricts water diffusion. Retrospectively assessed, the three
tumors with the lowest ADC before sacrifice were those that
still showed viable tumor cells in the necrotic center after the
third CA-4-P treatment (histologically proven). These three
tumors had also a smaller ADC value before the first CA-4-P
treatment, compared to the others.
Within the present tumor model and treatment strategy,
our results show that DW-MRI allows to differentiate be-
tween viable and nonviable tumor tissues. However, the
question as to the time point of the change from nonperfused
(including transient vascular function deficit) but viable tissue
to necrotic tumor tissue remains. Therefore, follow-up at
additional time intervals between 6 and 48 hours after drug
administration may provide more insights into the complex
nature of tumor damage from the use of VTAs.
Conclusion
The present data demonstrate that repeated CA-4-P admin-
istration, at the time intervals used, induces reproducible
effects on subcutaneously growing rhabdomyosarcomas in
rats. Similar results were obtained up to 2 days after each
drug administration, supporting the absence of drug-induced
resistance during this treatment course. DW-MRI is therefore
a promising noninvasive tool for in vivo monitoring of such
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treatment-induced changes and provides information on
both vascular changes as well as cellular integrity. Non-
invasively obtained early knowledge of response to therapy
is clinically useful. It helps in making decisions as to treat-
ment changes of individual patients, thereby preventing
unnecessary toxicity of prolonged ineffective treatment of
nonresponding tumors.
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